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Abstract. Fibrous tumors of the soft tissue are usually 
benign, but some fibrous neoplasms such as dermatofi- 
brosarcoma protuberans (DFSP), atypical fibroxanthoma 
(AFX), and malignant fibrohistiocytoma (MFH) can be 
very destructive locally with a high recurrence rate after 
local excision. On occasion, they can metastasize. Pre- 
vious reports have confirmed the high success rate of 
Mohs micrographic surgery for the treatment of DFSP, 
but data have been lacking on the potential benefit of this 
surgical approach for MFH and AFX tumors. Over the 
past 6 years, we have treated 17 patients with MFH (20 
tumors) and 5 patients with AFX with Mohs micrographic 
surgery. A retrospective analysis of the surgical results 
is presented. To date (average 3-year follow-up), all pa- 
tients contacted are tumor free with only one recurrence; 
no patient has developed metastatic disease. Our results 
to date are very encouraging; they lend support to Mohs 
micrographic surgery as a desired surgical approach for 
these diffiult-to-cure neoplasms. J Dermatol Surg Oncol 
1989; 15:1287-1292. 
INTRODUCTION 
Fibrohistiocytic tumors are a large and heteroge- 
neous group of soft-tissue neoplasms that are sim- 
ilar in their composition to cells resembling fibro- 
blasts and histiocytes. The histogenesis of these 
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tumors is uncertain, but they probably arise from 
mesenchymal cells that show partial histiocytic and/ 
or fibroblastic differentiation.’,’ The more malig- 
nant of these tumors retain some degree of pleu- 
ropotentiality . 
Fibrohistiocytic tumors can be classified accord- 
ing to their malignant potential. The most common 
fibrohistiocytic neoplasm is the benign dermatofi- 
broma, which has no invasive or malignant char- 
acteristics and rarely requires surgical intervention. 
Dermatofibrosarcoma protuberans (DFSP) is con- 
sidered a fibrohistiocytic sarcoma of intermediate 
malignancy. It bears a striking histologic similarity 
to the benign fibrous histiocytoma, but grows in a 
more infiltrative fashion, has a more marked 
tendency for local recurrence, and in rare instances 
can metas ta~ize .~ ,~  For this reason, DFSP was first 
described in 1924 as a ”progressive and recurring 
dermat~fibroma.”~ 
The malignant fibrous histiocytoma (MFH) may 
resemble a DFSP histologically but also shows nu- 
merous atypical mitotic figures and marked pleo- 
morphic cellularity. In addition to a high local re- 
currence rate, there is a significant metastatic rate 
usually associated with a poor p r o g n ~ s i s . ~ , ~  Prog- 
nosis and survival appears in part to be related to 
tumor depth. 
The atypical fibroxanthoma (AFX) is probably the 
most superficial or limited form of an MFH. Because 
of its superficial, intradermal location, it pursues a 
relatively benign course with a low recurrence rate 
and practically no metastatic potentiaL8 
The surgical management of these malignant fi- 
brohistiocytic tumors has been problematic and 
controversial due to the high recurrence rate, ag- 
gressive local infiltration, and metastatic potential. 
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The surgical process of treating DFSP with Mohs 
micrographic surgery has been well described in 
previous reports. At least 6 articles have appeared 
in the literature attesting to a high cure rate in a 
total of 26 patients.'-14 In addition, we have treated 
13 patients with DFSP using Mohs surgery (unpub- 
lished data) with no recurrences. It has been estab- 
lished that Mohs surgery is a preferred surgical mo- 
dality for DFSP. As Hanke13 states, "The limitations 
of standard vertical section histology may contrib- 
ute to recurrences of DFSP even when wide exci- 
sional margins were used. The microscopic exten- 
sions of DFSP can be easily traced out with Mohs 
micrographic surgery. DFSP should be considered 
a clear cut indication for Mohs micrographic 
surgery." 
However, the treatment of other neoplastic fi- 
brohistiocytic tumors (MFH and AFX) with Mohs 
surgery has not been as well established. The pur- 
pose of this article is to discuss our experience at 
the University of Michigan in treating MFH and 
AFX tumors with Mohs micrographic surgery. 
MATERIALS AND METHODS 
Over the past 6 years, we have treated a total of 22 
patients with 25 neoplastic fibrohistiocytic tumors 
using Mohs micrographic surgery. All patients 
were treated in an outpatient setting in the Cuta- 
neous Surgery and Oncology Unit. Local anes- 
thesia, usually 1 % lidocaine with epinephrine, was 
used for all patients. Standard horizontal frozen 
sections were prepared in the usual manner after 
appropriate mapping and staining of the excised tis- 
sue. The diagnosis of these fibrohistiocytic tumors 
preoperatively and tumor-free margins postopera- 
tively were confirmed by our dermatopathologist. 
In no instance was there any disagreement between 
our reading of these tumors on frozen section and 
what the dermatopathologist interpreted on per- 
manent sections. 
There were 20 MFH tumors seen in 17 patients 
and 5 AFX tumors seen in 5 patients. Eight patients 
were female and 14 patients were male. The average 
age was 50 years with a range between 14 and 84 
years of age. The location of these tumors was wide- 
spread, although there seemed to be a unique pre- 
dilection for the head and neck area. Eight tumors 
were located on the face, specifically, 5 on the nose. 
There were 5 lesions on the scalp, 6 on the trunk, 
2 on the ear, 1 on the arm, 1 in the mouth, and 1 
on the buttock. Twelve of these tumors were con- 
sidered primary and 11 were recurrent tumors, hav- 
ing been treated elsewhere with non-Mohs surgical 
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procedures, and 2 were incomplete excisions. The 
5 patients with AFX required an average of only one 
stage and four sections for clearing of the tumor. 
However, the patients with MFH required an aver- 
age of 2% stages and 16 sections. The preoperative 
size of these tumors averaged 3.0 X 2.3 cm with an 
average postoperative defect size of 4.8 x 3.5 cm. 
Most defects were repaired at the time of Mohs sur- 
gery after tumor-free margins were documented: 8 
defects by primary layered closure, 4 with flaps, 1 
with a full-thickness skin graft, and 2 by granula- 
tion. The largest defects required closure by referral 
to facial plastic surgeons. All patients were gener- 
ally pleased with their final cosmetic result. Figures 
1-5 document a clinical and histologic example. 
RESULTS 
The follow-up period on these patients has been an 
average of 3 years. We reviewed their progress and 
outcome by review of hospital and clinic records, 
as well as by telephone survey. The majority of pa- 
tients were seen on a regular basis every 6 months 
in our surgical follow-up clinic. Of the 22 patients 
who were treated, we have been able to contact 19 
(approximately 85%). Two patients have died of 
other causes unrelated to their fibrohistiocytic tu- 
mors. There has been recurrence of two tumors. 
One patient subsequently underwent a second 
Mohs micrographic procedure and continues to be 
tumor free for a 5-year period. The other patient 
had a local recurrence and a cutaneous metastatic 
lesion on the scalp. The patient presumably died of 
cardiovascular failure; it was uncertain whether 
there was visceral metastatic disease. Therefore, of 
the patients contacted, 94% were tumor free. Only 
one patient, described above, had probable meta- 
static disease. 
DISCUSSION 
Malignant fibrous histiocytoma is the most common 
soft-tissue sarcoma of late adult life.6 Many tumors 
previously described as pleomorphic variants of 
liposarcoma, fibrosarcoma, or rhabdosarcoma were 
probably mislabeled examples of MFH. The tumor 
typically appears between the ages of 50 and 70 
years.'j2 The average age in our patient population 
was 50 years. Malignant fibrohistiocytoma is 
slightly more common in males, and Caucasians are 
affected more commonly than blacks or Orientals. 
Clinically, the tumor presents as a painless, enlarg- 
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FIGURE 1. Preoperative surgical site of incompletely ex- 
cised MFH. 
FIGURE 2. Postoperative defect after 5 stages and 35 sec- 
tions with Mohs surgery. 
FIGURE 3. Primary closure of defect. 
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FIGURE 4. One-month follow-up. 
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FIGURE 5. 40 x magnification of MFH tumor cells. 
ing mass of several months duration. The tumors 
are usually solitary, may be multinodular, are pain- 
less, and can be as large as 5.0-10.0 cm in size. The 
average size in our patient population was about 
3.0 cm. Occasionally, fever and leukocytosis may 
occur with tumor presentation. The extremities are 
the most common site of involvement, especially 
the thigh, buttock, and limb skeletal muscles, al- 
though any area of the body can be involved. In our 
series, the tumor appeared to have an unusual pro- 
pensity for the head and facial areas. The retroper- 
itoneum is also a common site of involvement of 
deep MFH tumors, especially of the inflammatory 
type. MFX tumors have been classified as superfi- 
cial and deep. Superficial MFX tumors are confined 
to the subcutaneous tissue, but may be attached to 
fascia. Deep MFX tumors can extend from subcu- 
taneous tissue through fascia into muscle, or may 
be situated entirely within muscle. Most MFH tu- 
mors are deep lesions, with twice as many deeply 
situated tumors as superficial ones.7 MFH tumors 
may arise in the subcutaneous tissue and/or skin, 
although less than 10% are confined to the subcutis 
without evidence of deeper fascial involvement. 
Most of the tumors we treated were of this more 
superficial location, with origin in the skin or sub- 
cutis. The etiology of this aggressive tumor is un- 
clear. There is some circumstantial evidence that 
previous radiation exposure may be a predisposing 
f a ~ t o r , ' ~ * l ~  although only two of our patients had a 
previous history of such. 
The MFH manifests a broad range of histologic 
appearances and is divided into five subtypes, 
which are not mutually exclusive. ',2 The vast ma- 
jority of our patients showed the storiform, pleo- 
morphic pattern, which is the most common type. 
This tumor is classically composed of plump, pleo- 
morphic spindle cells, histiocytes, and numerous 
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multinucleated giant cells. The morphologic pattern 
is highly variable, with frequent transitions from 
storiform areas to pleomorphic areas. Focal myxoid 
change is common. Although such tumors may re- 
semble DFSP, there are distinctive histologic differ- 
ences. The numerous atypical mitotic figures, less 
prominent storiform pattern, marked pleomor- 
phism, and typical foam and giant cells are all key 
differential elements. Histologically, the differential 
diagnosis of MFH also includes leiomyosarcoma, 
pleomorphic variants of lip0 and rhabdomyosar- 
coma, epitheloid sarcoma, and histiocytic lym- 
phoma. Headington et al.I7 define the key diagnos- 
tic criteria for MFH as threefold: (1) a nodular 
neoplasm similar to the histologic pattern of DFSP; 
(2) angioinvasion; and (3)  frequent penetration of 
the subcutis and deeper tissue. 
Although the MFH has a clinical appearance of 
being a circumscribed tumor, it often spreads for 
considerable distances along fascial planes or be- 
tween muscle fibers.' This invasive behavior ac- 
counts for its high rate of local recurrence, esti- 
mated to be 40-50%, even after wide local excision. 
Unfortunately, the metastatic rate is also in the 
range of 40-50% with a high associated mortality. 
The 2-year survival rate is only 60% .6 Metastatic dis- 
ease usually occurs within 2 years of diagnosis, 
most frequently to the lung (82%), lymph node 
(32%), liver (15%), and bone (15%).6 The depth and 
size of the tumor appears to correlate best with the 
risk of metastatic ~ p r e a d . ~  Fewer than 10% of tu- 
mors confined entireIy to the subcutis without 
deeper fascial or muscle involvement metastasize. 
Certainly, one of the reasons for our excellent re- 
sults to date may be related to the fact that most of 
the MFH tumors we treated were smaller (average 
3.0 cm) and more superficial (skin and subcutis), 
although extension to fascia and muscle was en- 
countered. 
Headington et al. l7 have previously noted that 
there is every indication that the superficially lo- 
cated MFH tumors have a prognosis that is superior 
to those tumors arising in deeper soft tissue. MFH 
tumors of the retroperitoneum have the worst prog- 
nosis. Patients with distally located tumors have a 
better 5-year survival than proximally located tu- 
m o r ~ . ~  Histologic features, including degree of an- 
aplasia and the number of mitoses, appear to have 
little prognostic value. 
Because this tumor spreads a considerable dis- 
tance beyond the gross tumor mass, an aggressive, 
wide, and deep local excision or even possible am- 
putation have been recommended. We felt that 
Mohs surgery was well suited for the treatment of 
this invasive tumor, particularly when confined to 
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a more superficial location. Mohs micrographic sur- 
gery is capable of tracing out the deepest and wid- 
est extensions of the tumor as it spreads under- 
neath the normal-appearing skin. Mohs surgery 
allowed for complete removal of the tumor while 
preserving as much normal tissue as feasible, which 
is of great cosmetic importance in the head and fa- 
cial regions. Weiman and Ceilley” have previously 
described the successful use of Mohs surgery using 
permanent paraffin embedded sections in treating 
one patient with a myxoid variant of MFH. Our re- 
sults to date would concur that Mohs surgery is an 
extremely effective surgical modality for treatment 
of these difficult tumors. 
In addition, we treated five patients with atypical 
fibrous xanthomas, which is considered to be a su- 
perficial form of an MFH. Initially, AFX was inter- 
preted as a benign reactive lesion, but because of 
its histologic similarity to MFH and because of the 
occasional occurrence of metastatic disease in re- 
gional lymph nodes, it is now regarded as a neo- 
plasm of low-grade malignancy.” This tumor is 
seen most often in actinically damaged skin on the 
head and neck of elderly patients. Clinically, it ap- 
pears as an asymptomatic, solitary nodule or ulcer, 
most commonly on the nose, cheek, and ear. How- 
ever, it has been rarely described on the trunk and 
extremities, usually in younger persons.” The tu- 
mor is usually less than 2.0 cm in size; the appear- 
ance is not distinctive and often must be differen- 
tiated from a squamous cell carcinoma, basal cell 
carcinoma, or pyogenic granuloma. Occasionally, 
the tumor is eroded or ulcerated. It is histologically 
indistinguishable from pleomorphic forms of MFH, 
but does not invade subcutis or deeper structures 
such as fascia or muscle. Pleomorphism, particu- 
larly in the form of bizarre xanthomatous cells, is 
the cytologic hallmark of the AFX.”T’~ A w ell- 
developed storiform pattern is rarely noted in AFX. 
Necrosis, which is a prominent feature of MFH, is 
rarely seen and if present to a significant degree, 
should raise the question of a proper diagnosis of 
AFX. Because the AFX is considered an early form 
of MFH, the distinction of the two is to some extent 
arbitrary, but it is important to separate them be- 
cause of their differing natural histories. AFX, due 
to its in situ dermal location and less invasive na- 
ture, has a much better prognosis than MFH. In the 
largest series in the literature, only 9 out of 140 pa- 
tients developed a recurrence, and no metastatic le- 
sions were found.’ However, in rare instances, this 
tumor can metastasize, and an apparent AFX can 
progress to an MFH. l9 If only a portion of the entire 
tumor is submitted for pathologic interpretation, 
such as in a shave biopsy, it is sometimes difficult 
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to assess the true depth and nature of invasion. 
All of the AFX tumors that we treated were pri- 
mary neoplasms, relatively small, and easily cleared 
with one stage of Mohs surgery. Although a con- 
servative fusiform excision may have been suffi- 
cient treatment, Mohs surgery assured us of totally 
free margins with no invasion of deeper subcuta- 
neous layers. It also conserved tissue in important 
facial areas. 
In conclusion, we have now treated a total of 
25 neoplastic fibrohistiocytic tumors (excluding 
DFSP). The results to date have been extremely en- 
couraging with an average tumor-free interval of 3 
years. Certainly, follow-up over the ensuing years 
will be necessary to better define the long-term sur- 
vival rate. Surgery was well tolerated with negligi- 
ble morbidity and high patient acceptance. Mohs 
surgery offered a precise surgical approach for the 
removal of these invasive, recurrent, and poten- 
tially metastatic fibrohistiocytic tumors. Consider- 
able cosmetic benefit was obtained, especially in the 
facial areas, by avoiding unnecessary wide local ex- 
cisions. In comparison to cure rates quoted in the 
literature with other surgical procedures, Mohs sur- 
gery appears to have an excellent chance of local 
control and no metastatic disease. The more super- 
ficial location and relatively smaller size of the tu- 
mors we treated may also have contributed to our 
successful cure rate. For these reasons, we strongly 
recommend the use of Mohs surgery for the surgical 
treatment of neoplastic fibrohistiocytic tumors, spe- 
cifically malignant fibrous histiocytoma and atypical 
fibrous xanthomas. 
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